GFC Therapy vs PRP
GFC therapy and PRP are autologous blood-derived knee injections, but they are not identical or universally standardised. PRP concentrates platelets in plasma; GFC systems generally aim to activate platelets and separate a growth-factor-rich preparation with fewer intact blood cells. The clinically important question is not which label sounds newer, but whether the selected product is appropriate for the diagnosis, arthritis stage and functional goal.
Quick Comparison
Both begin with the patient’s own blood.
PRP delivers a platelet-rich preparation with variable platelet and white-cell content.
GFC aims to deliver released growth factors with reduced cellular content, but systems and protocols differ.
PRP has a larger published evidence base and is discussed in major guidelines.
GFC-specific clinical evidence is emerging, and direct high-quality comparison with characterised PRP remains limited.
Neither treatment is a stem-cell injection or proven cartilage-regeneration cure.
What Is PRP?
Platelet-rich plasma is produced by centrifuging blood to obtain plasma with platelet concentration above baseline. Final platelet count, leukocyte content, red-cell contamination, activation and injection volume differ between systems. “PRP” therefore describes a family of preparations rather than one standard medicine.
Read PRP Injection for Knee Arthritis.
What Is GFC?
Growth Factor Concentrate is also prepared from the patient’s blood. Commercial systems are designed to activate platelets and collect a growth-factor-rich liquid with fewer intact cellular components. The exact composition depends on the device, incubation, processing and collection protocol. GFC is not one universally accepted generic formulation, and results from one commercial system cannot automatically be applied to another.
Read GFC Therapy for Knee Arthritis.
Which Has More Evidence?
PRP has a substantially larger research base, although heterogeneity remains important. AAOS states that PRP may reduce pain and improve function but gives a limited-strength recommendation; ACR strongly recommends against PRP because preparations and techniques are not standardised.
A 2024 systematic review of GFC identified only three eligible clinical studies and concluded that more adequately powered multicentre randomised trials and direct comparisons with other orthobiologics were needed. Additional studies have since appeared, but GFC-specific evidence remains smaller and often relates to particular systems, comparison groups or protocols.
Do Major Guidelines Endorse GFC Separately?
Major knee-osteoarthritis guidelines generally discuss platelet-rich plasma or intra-articular biologic injections rather than providing a separate recommendation for every commercial GFC system. It would therefore be misleading to describe GFC as independently guideline-approved or guideline-preferred. The absence of a separate recommendation is not proof of ineffectiveness; it reflects limited and non-standardised evidence.
Is GFC Better Than PRP?
There is no dependable universal winner. Direct GFC-versus-PRP trials are limited, and studies may use different platelet concentrations, growth-factor profiles, injection schedules, arthritis grades and outcome measures. Lower cellular content may reduce inflammatory soreness in some preparations, but it does not guarantee a better clinical result.
Who May Be Considered for Either Injection?
Selected patients with symptomatic mild or moderate knee osteoarthritis.
Symptoms that match the knee and compartment shown on examination and imaging.
Persistent limitation despite appropriate exercise and first-line care.
No active infection or relevant blood-related contraindication.
Realistic acceptance that benefit may be partial, delayed or absent.
Willingness to continue rehabilitation and weight management when relevant.
Who Is Less Likely to Benefit?
Advanced bone-on-bone arthritis with major deformity.
Severe stiffness, instability or constant disabling pain.
Pain mainly arising from the hip, spine, nerves or another diagnosis.
A previous correctly performed blood-derived injection with no meaningful benefit.
Expectation of guaranteed cartilage regrowth or permanent avoidance of replacement.
How the Procedures Differ in Practice
The diagnosis, arthritis stage, medicines and treatment goal are reviewed.
Blood is collected from the patient.
The sample is processed using the identified PRP or GFC system.
The final preparation is separated and documented.
The knee is cleaned using sterile technique and the preparation is injected.
Activity, medicine, warning-sign and rehabilitation instructions are provided.
The patient should know the exact product or system, number of injections, total cost and reason for the selected protocol before treatment begins.
Expected Results and Duration
Some patients report reduced pain and improved function over several weeks; others obtain limited or no benefit. No fixed pain-free period should be promised. The response should be measured using walking distance, stairs, sleep, rescue-medicine use and participation in exercise rather than pain score alone.
Number of Injections
PRP may be used as one injection or a short series. GFC systems may follow product-specific protocols. More injections do not automatically provide greater benefit, and a fixed commercial package should not replace individual clinical judgement.
Risks and Aftercare
Temporary soreness, swelling or stiffness.
Bruising from blood collection or injection.
Rare joint infection.
No meaningful clinical improvement.
Cost without durable functional benefit.
Patients should not stop prescribed medicines independently. Severe worsening pain, fever, a hot red knee or inability to bear weight requires urgent assessment.
Cost and Value
Both treatments are commonly paid for directly. A newer, more expensive or more concentrated preparation is not automatically more effective. Value depends on the probability, magnitude and duration of functional benefit, the total number of visits and the alternatives available.
Can GFC or PRP Regrow Cartilage?
Neither has been proven to restore advanced cartilage loss to a normal joint. Laboratory growth-factor effects, biomarkers or exploratory imaging findings should not be converted into a guarantee of clinical cartilage regeneration. The realistic goal is possible symptom and function improvement in a selected patient.
Using the Treatment Window
When symptoms improve, the patient should use that period to rebuild strength, walking tolerance and confidence. An injection without progressive rehabilitation may provide limited value.
Read Physiotherapy for Knee Arthritis.
What if the Injection Does Not Work?
A failed treatment should prompt reassessment of the diagnosis, arthritis progression, product used, injection placement and rehabilitation plan. Automatically repeating or switching products may add cost without addressing the main problem.
Read When Knee Injections Stop Working.
When Injections Should Not Delay Replacement
Repeated blood-derived injections cannot correct severe deformity, major instability or advanced joint destruction. When pain substantially affects sleep, walking and independence despite appropriate care, knee replacement should be discussed honestly.
Read When Does Knee Arthritis Need Replacement?.
Questions Patients Commonly Ask
Is GFC the same as PRP?
No. Both begin with blood, but the processing aims and final preparations differ.
Which has stronger evidence?
PRP has a larger evidence base. GFC research is emerging, with fewer studies and limited direct comparison.
Does GFC cause less pain than PRP?
Some systems are designed to reduce cellular content and may cause less inflammatory soreness, but this does not guarantee less pain or better results.
Are GFC and PRP stem-cell treatments?
No. They are blood-derived preparations.
Can either prevent knee replacement?
They may reduce symptoms enough that surgery is not currently required in selected patients, but cannot guarantee permanent avoidance.
Which should I choose?
The decision should use diagnosis, arthritis stage, product transparency, evidence, cost, previous response and patient preference—not a claim that one label is universally superior.
Clinical References
Systematic Review: Growth Factor Concentrate for Knee Osteoarthritis
Randomized Trial of Growth Factor Concentrate in Knee Osteoarthritis
AAOS Clinical Practice Guideline: Management of Osteoarthritis of the Knee
American College of Rheumatology Osteoarthritis Guideline
About Dr. Mayur Rabhadiya
Dr. Mayur Rabhadiya is an Orthopedic and Joint Replacement Surgeon in Mumbai. Qualifications: MBBS, D’Ortho, DNB (Orthopedics), MNAMS (Orthopedics), FIJR (Robotic & Navigation). Read his professional profile.
Book a Consultation
Consultations are available in Ghatkopar East and Ghatkopar West, Mumbai. Call or WhatsApp +91 84249 03913 or +91 96113 30063, or use the appointment page.
Medical Disclaimer
This guide provides general education and does not replace individual examination, injection consent or treatment advice.